Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in upcoming investor conferences, featuring fireside chats with management. The events include the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 10:30 am EST and the Piper Sandler 34th Annual Healthcare Conference on December 1 at 12:00 pm EST. Audio webcasts and recordings will be accessible on Chinook's website, available for replay for 90 days. Chinook focuses on developing precision medicines for kidney diseases, with lead programs targeting IgA nephropathy and related disorders.

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:

• 5^th Annual Evercore ISI HealthCONx Conference – Fireside chat on Tuesday, November 29^th at 10:30 am EST
  
  
• Piper Sandler 34^th Annual Healthcare Conference – Fireside chat on Thursday, December 1^st at 12:00 pm EST  
  

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

What is Chinook Therapeutics scheduled to participate in with the stock symbol KDNY?

Chinook Therapeutics is participating in the 5th Annual Evercore ISI HealthCONx Conference on November 29 and the Piper Sandler 34th Annual Healthcare Conference on December 1.

When will Chinook Therapeutics hold its fireside chat at Evercore ISI HealthCONx Conference?

The fireside chat at the Evercore ISI HealthCONx Conference is scheduled for November 29 at 10:30 am EST.

Where can I access Chinook Therapeutics' audio webcasts?

Audio webcasts of Chinook Therapeutics' presentations can be accessed on their website and will be available for 90 days after the events.

What are the key programs being developed by Chinook Therapeutics (KDNY)?

Chinook Therapeutics is developing several programs, including atrasentan for IgA nephropathy, BION-1301 for IgA nephropathy, and CHK-336 for hyperoxalurias.

What is the focus of Chinook Therapeutics in the biopharmaceutical sector?

Chinook Therapeutics focuses on discovering and developing precision medicines for rare and severe chronic kidney diseases.